Genenta Science
Biotechnology company that develops gene transfer therapy for the treatment of cancer tumors.
Launch date
Employees
Market cap
CAD99.4m
Enterprise valuation
CAD71m (Public information from Sep 2024)
Share price
$3.85 GNTA
Company register number MI2045555
Milan Lombardy (HQ)
Financials
Estimates*
| EUR | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| EBITDA | (5.6m) | (5.5m) | (13.3m) | (11.5m) | (19.0m) | (30.3m) | (38.1m) |
| Profit | (5.6m) | (5.5m) | (8.5m) | (11.6m) | (18.5m) | (24.1m) | (29.9m) |
| EV / EBITDA | - | -31.7x | -7.0x | -7.1x | -3.4x | -2.1x | -1.7x |
| R&D budget | 4.7m | 3.4m | 5.3m | 6.5m | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
N/A | Spinout | ||
$7.2m | Series A | ||
$3.8m | Series A | ||
* | €7.0m | Series B | |
* | €13.2m | Early VC | |
* | N/A | $40.0m | IPO |
| Total Funding | CAD45.3m | ||
Related Content
Recent News about Genenta Science
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.